Goodluck Capital

Suven Life Sciences has broken out of a Cup and Handle pattern on its highest trading volume in months.

✅ Revenue stood at Rs 2.1 crore.
✅ Net loss was Rs 276 crore. R&D spending was Rs 292 crore.
✅ The company carries zero debt.

A breakout can draw attention and bring in momentum-driven buying. But in biotech, the only thing that ultimately matters is the clinical trial data. Everything else is speculation until that data arrives.

Disclaimer: This is an educational post. Not investment advice.

Nifty50 Analysis | 5 July 📊

Nifty closed at 24,270 last week, its highest level in nearly two months and the fourth consecutive weekly gain. India VIX dropped nearly 10% to 11.79.

Nifty has broken above its short-term trendline resistance without strong buying momentum behind it. The index is moving higher, but the conviction of a sustained uptrend is not fully there yet. That distinction matters for how aggressively investors should position right now.

The levels that matter this week:

1️⃣ 24,300 to 24,500 is the immediate resistance zone. If Nifty breaks above this with strong buying volume, the next target opens up toward 25,000 to 25,100. That would be a meaningful move and worth watching for closely.

2️⃣ 24,000 to 23,900 is the first support on the downside. As long as this holds, the recent structure remains intact.

3️⃣ 23,500 to 23,400 becomes the next support if the market slips below the first zone.

Three factors are likely to drive direction this week.

👉 Q1 earnings season begins, with TCS kicking things off. Earnings commentary, especially around demand and margins, will set the tone for how the broader market reacts to results over the coming weeks.

👉 Developments in the Middle East remain a live variable that can shift sentiment quickly in either direction.

👉 And crude oil prices, which have stayed stable and supported the rally so far, are worth monitoring for any sharp reversal.

Our view is that Nifty is currently trading in a 24,000 to 24,500 range. A decisive break above 24,500 would open the path toward 25,000. Until that happens, chasing the index does not offer a particularly attractive risk to reward setup.

A stock-specific approach with proper risk management continues to make more sense in this phase. The best opportunities right now are more likely to be found in individual names with strong earnings visibility than in the index itself.

Disclaimer: This is an educational post. Not investment advice. Please do your own research before making any investment decision. Past performance does not guarantee future returns.

Best Performing Asset Class in India by 10 Year CAGR, as of June 2026

This 10 year CAGR data is most useful for reviewing whether your current asset allocation actually reflects where returns have been generated over the long term. If your portfolio is heavily weighted toward real estate and fixed deposits, this data gives a factual basis to evaluate whether that allocation is still appropriate.

Equally, it is important to note that gold's exceptional performance over this specific decade was partially driven by extraordinary global events. Future returns from any asset class should not be extrapolated from a period with this level of geopolitical disruption.

Source: RBI Handbook of Statistics, Fund Fact Sheets, NSE Indices. Data as of June 2026. Not investment advice. Past performance does not guarantee future returns.

Stock Analysis is Live - 30 June 2026 🔥📈

💡 Buy Carborundum Universal
NSE: CARBORUNIV
💼 Sector: Manufacturing

◽ Best Buy Range: 1170 - 1190
◽ Sell Target: 1250 - 1270
◽ Stop-Loss: Below 1115

💰 General Target: 6% - 8%
🗓️ Approx trade duration: 12 - 14 days

Disclaimer: This is an educational post. Not investment advice. Please do your own research before investing.